Strides Pharma Science Limited

NSEI:STAR Stock Report

Market Cap: ₹80.6b

Strides Pharma Science Dividend

Dividend criteria checks 1/6

Strides Pharma Science is a dividend paying company with a current yield of 0.17%.

Key information

0.2%

Dividend yield

-6%

Payout ratio

Industry average yield0.7%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per share-₹16.59
Dividend yield forecast in 3Y0.4%

Recent dividend updates

Strides Pharma Science (NSE:STAR) Has Announced That It Will Be Increasing Its Dividend To ₹2.50

Jul 28
Strides Pharma Science (NSE:STAR) Has Announced That It Will Be Increasing Its Dividend To ₹2.50

Recent updates

Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)

Apr 04
Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Feb 29
Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story

Dec 23
Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story

We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt

Sep 26
We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Jun 08
Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Aug 02
Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Is Strides Pharma Science (NSE:STAR) A Risky Investment?

Jun 25
Is Strides Pharma Science (NSE:STAR) A Risky Investment?

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Dec 21
Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Strides Pharma Science (NSE:STAR) Has Announced That It Will Be Increasing Its Dividend To ₹2.50

Jul 28
Strides Pharma Science (NSE:STAR) Has Announced That It Will Be Increasing Its Dividend To ₹2.50

Estimating The Fair Value Of Strides Pharma Science Limited (NSE:STAR)

Apr 13
Estimating The Fair Value Of Strides Pharma Science Limited (NSE:STAR)

Should Strides Pharma Science Limited (NSE:STAR) Be Part Of Your Dividend Portfolio?

Mar 04
Should Strides Pharma Science Limited (NSE:STAR) Be Part Of Your Dividend Portfolio?

These 4 Measures Indicate That Strides Pharma Science (NSE:STAR) Is Using Debt Extensively

Feb 15
These 4 Measures Indicate That Strides Pharma Science (NSE:STAR) Is Using Debt Extensively

Can Mixed Fundamentals Have A Negative Impact on Strides Pharma Science Limited (NSE:STAR) Current Share Price Momentum?

Jan 26
Can Mixed Fundamentals Have A Negative Impact on Strides Pharma Science Limited (NSE:STAR) Current Share Price Momentum?

The Strides Pharma Science (NSE:STAR) Share Price Is Up 140% And Shareholders Are Boasting About It

Jan 11
The Strides Pharma Science (NSE:STAR) Share Price Is Up 140% And Shareholders Are Boasting About It

Who Has Been Selling Strides Pharma Science Limited (NSE:STAR) Shares?

Dec 28
Who Has Been Selling Strides Pharma Science Limited (NSE:STAR) Shares?

Are Strides Pharma Science's (NSE:STAR) Statutory Earnings A Good Guide To Its Underlying Profitability?

Dec 10
Are Strides Pharma Science's (NSE:STAR) Statutory Earnings A Good Guide To Its Underlying Profitability?

Could The Strides Pharma Science Limited (NSE:STAR) Ownership Structure Tell Us Something Useful?

Nov 25
Could The Strides Pharma Science Limited (NSE:STAR) Ownership Structure Tell Us Something Useful?

Insider Buying: The Strides Pharma Science Limited (NSE:STAR) Non-Executive Director Just Bought 52% More Shares

Aug 17
Insider Buying: The Strides Pharma Science Limited (NSE:STAR) Non-Executive Director Just Bought 52% More Shares

What You Can Learn From Strides Pharma Science Limited's (NSE:STAR) P/E

Aug 11
What You Can Learn From Strides Pharma Science Limited's (NSE:STAR) P/E

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: STAR's dividend payments have been volatile in the past 10 years.

Growing Dividend: STAR's dividend payments have fallen over the past 10 years.


Dividend Yield vs Market

Strides Pharma Science Dividend Yield vs Market
How does STAR dividend yield compare to the market?
SegmentDividend Yield
Company (STAR)0.2%
Market Bottom 25% (IN)0.3%
Market Top 25% (IN)1.2%
Industry Average (Pharmaceuticals)0.7%
Analyst forecast in 3 Years (STAR)0.4%

Notable Dividend: STAR's dividend (0.17%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.26%).

High Dividend: STAR's dividend (0.17%) is low compared to the top 25% of dividend payers in the Indian market (1.18%).


Earnings Payout to Shareholders

Earnings Coverage: STAR is paying a dividend but the company is unprofitable.


Cash Payout to Shareholders

Cash Flow Coverage: With its low cash payout ratio (4.5%), STAR's dividend payments are thoroughly covered by cash flows.


Discover strong dividend paying companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.